Lv4
410 积分 2025-07-15 加入
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials
19天前
已完结
HFpEF and MASLD: converging mechanisms and clinical implications
19天前
已完结
Association of long-term ambient fine particulate matter (PM2.5) and incident non-alcoholic fatty liver disease in Chinese adults
19天前
已完结
Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease
19天前
已完结
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis
22天前
已完结
Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis
22天前
已完结
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials
22天前
已完结
Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study)
22天前
已完结
Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts
22天前
已完结
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
22天前
已完结
皖公网安备34019202002308
